Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent and Lilly Report MabThera/Rituxan Biosimilar Meets Endpoints

publication date: May 14, 2019

Suzhou's Innovent and its partner Lilly announced their anti-CD20 biosimilar to rituximab (MabThera/Rituxan) met its primary endpoints in two China clinical trials. The candidate, IBI301, was compared to rituximab in a Phase III trial in patients with diffuse large B-cell lymphoma and also in a pharmacokinetic (PK) study in patients with CD20-positive B-cell lymphoma. The Roche/Genentech drug is the only one in its class available for DLBCL in China; if approved, the Innovent/Lilly biosimilar will offer a less expensive alternative. More details....

Stock Symbols: (HK: 01801) (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.